Internal Medicine Doctors in Lanoka Harbor, NJ Accepting Medicare
2 Internal Medicine doctors found. Showing 1 - 2
 Avelina Fernando Flores, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 411 Rte 9, Ste 6, Lanoka Harbor, NJ 08734 Phone: 609-971-1711 Fax: 609-971-3390 |
 Mr. Victor C Tauro, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 411 Rt 9, Suite 6, Lanoka Harbor, NJ 08734 Phone: 609-971-1711 Fax: 609-971-3390 |
News Archive
Event addresses how TV can raise awareness of global health issues
At an event in Washington, D.C., on Wednesday sponsored by the Hollywood, Health & Society program of the University of Southern California, panelists discussed how television storylines can raise the American public's awareness of global health issues, the Washington Examiner's blog, "Yeas & Nays," reports (Schwab/Palmeri, 3/25).
Study may lead to new insights on use of aspirin in GI cancer
Aspirin improves survival in patients with tumours situated throughout the gastrointestinal (GI) tract, results from a large study in The Netherlands show. This is the first time that survival data from patients with tumours in different GI locations have been analysed at the same time; previously, only one type of cancer, usually colorectal, was studied.
Researchers use magnets to control tiny DNA-based robots
Researchers have devised a magnetic control system to make tiny DNA-based robots move on demand-;and much faster than recently possible.
WHO cautions Thailand against issuing compulsory license for antiretroviral Kaletra
The World Health Organization on Thursday cautioned the Thai government on its decision to allow the country to produce a lower-cost version of Abbott Laboratories' antiretroviral drug Kaletra by granting a compulsory license for the drug, the Bangkok Post reports.
Hypertension drug market to decrease through 2013 due to generic erosion and few emerging therapies
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to extensive generic erosion, the hypertension drug market will be constrained through 2018 by a pipeline containing very few emerging therapies with novel mechanisms of action. Gilead's darusentan was positioned to be the next emerging therapy with a novel mechanism of action to reach the hypertension market. However, following darusentan's failure to meet its primary endpoint in the recent DORADO-AC Phase III clinical trial, further development of the agent has been terminated.
› Verified 8 days ago